GeminiMab technology
GSK Secures Exclusive Rights to Syndivia’s Preclinical Prostate Cancer ADC in $357 Million Deal
GSK; Syndivia; ADC; prostate cancer; metastatic castration-resistant prostate cancer; exclusive licensing; oncology pipeline; GeminiMab technology; milestone payments; preclinical asset